An international collaboration between Bruce Power, Isogen (a Kinectrics and Framatome company), and ITM Isotope Technologies Munich SE (ITM) announced they have begun commercial production of lutetium-177 using Unit 7 of the Bruce nuclear power plant in Kincardine, Ontario. According to the companies, this marks the first time a commercial power reactor has been used to commercially produce short-lived medical radioisotopes.

An international collaboration between Bruce Power, Isogen (a joint venture of Kinectrics and Framatome), and ITM Isotope Technologies Munich SE, announced a milestone marking the first time that lutetium-177, a short-lived medical radioisotope, has been produced in a commercial nuclear power reactor.

The Canadian Nuclear Safety Commission and the U.S. Nuclear Regulatory Commission have completed the first collaborative project under a two-year-old memorandum of cooperation (MOC) aimed at enhancing technical reviews of advanced reactor and small modular reactor technologies, the CNSC announced earlier this week.

The project, a 23-page joint report from the regulators on a white paper submitted last July by X-energy regarding reactor pressure vessel (RPV) construction code specifications for the company’s Xe-100 SMR, was released to the public on August 6. The Xe-100 is an 80-MWe unit that can be scaled into a “four-pack” 320-MWe power plant, according to X-energy.